Physician profile
Rohit Kakar
NPI 1992069462
$39,599.85
in general payments reported to CMS, 2019-2025
22 companies · $28K in 2025
The $28K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $39.84 · 2022: $77.28 · 2023: $668 · 2024: $9,876 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,800 · Food and Beverage: $3,906 · Travel and Lodging: $3,548 · Education: $33.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,417.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,800.00 |
| Food and Beverage | $3,906.29 |
| Travel and Lodging | $3,547.73 |
| Education | $33.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $24,310.68 | 2025 | Dysport, Aklief, Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $8,564.53 | 2023-2024 | Sotyktu |
| Abbvie INC. | $3,698.31 | 2020-2025 | |
| Celgene Corporation | $875.42 | 2019-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $480.90 | 2023-2025 | |
| Merz North America, INC. | $294.87 | 2019-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $290.26 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $220.34 | 2019 | |
| Ucb, INC. | $197.07 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $128.61 | 2019-2025 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $89.28 | 2020-2024 | Tremfya |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Leo Pharma INC. | $66.31 | 2019-2025 | Adbry |
| Pfizer INC. | $65.94 | 2023-2024 | |
| Lilly USA, LLC | $56.71 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aclaris Therapeutics, INC. | $49.16 | 2019 | |
| Almirall LLC | $39.50 | 2019 | |
| Amgen INC. | $24.57 | 2025 | Otezla |
| Biofrontera INC. | $23.14 | 2019 | |
| Genzyme Corporation | $22.05 | 2024 | |
| Epi Health, LLC | $19.51 | 2019 | |
| Arcutis Biotherapeutics, INC. | $15.12 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Kakar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.